Literature DB >> 3300969

Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.

G Y Locker, T Hoeltgen, L Kilton, S Krauss, M McNamara, R Blough, C Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3300969

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.

Authors:  G Somlo; J Doroshow; S Akman; L Leong; K Margolin; M McNamara; P Multhauf; D Blayney; R Morgan; J Raschko
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

2.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.

Authors:  W P McGuire; J A Blessing; M L Berman
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

3.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; E Yordan; J Beecham
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.